Premier Pharmacy Labs Recalls Products Due to Sterility Concerns
Premier Pharmacy Labs is voluntarily recalling multiple products because of the potential lack of sterility assurance.
Premier Pharmacy Labs announced on April 11, 2018 that it was voluntarily recalling products because of a potential lack of sterility assurance. The recall was initiated after the company detected microbial contamination during routine testing of subsequent unreleased product lots. An interaction between the product syringe and tamper-evident container closure was found. The company stated in a press release that this interaction may result in the potential introduction of microorganisms.
While the company has not yet received any complaints about adverse events, it warns that use of “non-sterile injection products that are intended to be sterile may result in a site-specific or systemic infection, which in turn may cause hospitalization, significant morbidity (permanent organ damage), or a fatal outcome.”
Products affected by the recall, which were distributed nationwide to hospital pharmacies, clinics, and healthcare facilities, include the following:
- Morphine Sulfate (Single Dose Syringe) 2mg/mL Preservative Free Injection
- Morphine Sulfate (Single Dose Syringe) 4mg/mL Preservative Free Injection
- Hydromorphone HCL (Single Dose Syringe) 1mg/mL Preservative Free Injection
- Neostigmine Methylsulfate (Single Dose Syringe) 1mg/mL Injection.
More product information, including lot numbers and beyond use dates, can be found on FDA’s website.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
